Factores de Risco Social, Comportamental e Biológico de Gravidez na Adolescência: Estudo de Caso-Controlo

Introdução: O melhor conhecimento dos factores de risco da gravidez na adolescência, especialmente a não desejada, pode ser uma forma de contribuir para a sua prevenção. Objectivo: Determinar possíveis factores de risco sociais, comportamentais e biológicos de gravidez na adolescência. Métodos: Estudo de caso-controlo comparando adolescentes grávidas (casos) com adolescentes que nunca estiveram grávidas (controlos). Foram analisados factores de risco (a) social: índice de Graffar, tipo de família, rendimento escolar e abandono escolar; (b) comportamental: hábitos de dependência, coitarca, contracepção e número de parceiros sexuais; e (c) biológico: idade, menarca, regularidade dos ciclos menstruais, índice de massa corporal e perturbações da saúde mental. Resultados: Foram incluídas 50 jovens em cada grupo, emparelhadas por idade. Os factores de risco de gravidez encontrados com significado estatístico foram (a) sociais: índice de Graffar ≥4 (OR: 4,96; IC 95%: 1,96-12,74), família não nuclear (OR: 4,64; IC 95%: 1,83-11,98), reprovações prévias (OR: 8,84; IC 95%: 3,20-25,16) e abandono escolar (OR: 9,01; IC 95%: 3,34-24,96); (b) comportamentais: hábitos de dependência (OR: 8,43; IC 95%: 1,65-57,87) e não utilização de contracepção (OR: 44,33; IC 95%: 5,05-100,92); e (c) biológicos: idade de menarca <12 anos (OR: 5,25; IC 95%: 1,89-15,02), irregularidade dos ciclos menstruais (OR: 4,51; IC 95%: 1,74-11,91) e índice de massa corporal >percentil 85 (OR: 2,95; IC 95%: 1,04-8,55). Não se revelaram factores de risco de gravidez a existência de mais de um parceiro sexual (OR: 4,42; IC: 0,5-99,31), idade de coitarca <15 anos (OR: 5,11; IC 95%: 0,93-36,71) e as perturbações da saúde mental (OR=1; IC 95%=0,15-6,63). Conclusão: Na promoção da saúde sexual e reprodutiva sugere-se que se dê atenção privilegiada às jovens de meio desfavorecido, de famílias não nucleares, com insucesso escolar, hábitos de dependência, idade menor de menarca, ausência de contracepção, irregularidade menstrual e excesso de peso.

Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study)

OBJECTIVE: Combined hyperlipidaemia is a common and highly atherogenic lipid phenotype with multiple lipoprotein abnormalities that are difficult to normalise with single-drug therapy. The ATOMIX multicentre, controlled clinical trial compared the efficacy and safety of atorvastatin and bezafibrate in patients with diet-resistant combined hyperlipidaemia. PATIENTS AND STUDY DESIGN: Following a 6-week placebo run-in period, 138 patients received atorvastatin 10mg or bezafibrate 400mg once daily in a randomised, double-blind, placebo-controlled trial. To meet predefined low-density lipoprotein-cholesterol (LDL-C) target levels, atorvastatin dosages were increased to 20mg or 40mg once daily after 8 and 16 weeks, respectively. RESULTS: After 52 weeks, atorvastatin achieved greater reductions in LDL-C than bezafibrate (percentage decrease 35 vs 5; p < 0.0001), while bezafibrate achieved greater reductions in triglyceride than atorvastatin (percentage decrease 33 vs 21; p < 0.05) and greater increases in high-density lipoprotein-cholesterol (HDL-C) [percentage increase 28 vs 17; p < 0.01 ]. Target LDL-C levels (according to global risk) were attained in 62% of atorvastatin recipients and 6% of bezafibrate recipients, and triglyceride levels <200 mg/dL were achieved in 52% and 60% of patients, respectively. In patients with normal baseline HDL-C, bezafibrate was superior to atorvastatin for raising HDL-C, while in those with baseline HDL-C <35 mg/dL, the two drugs raised HDL-C to a similar extent after adjustment for baseline values. Both drugs were well tolerated. CONCLUSION: The results show that atorvastatin has an overall better efficacy than bezafibrate in concomitantly reaching LDL-C and triglyceride target levels in combined hyperlipidaemia, thus supporting its use as monotherapy in patients with this lipid phenotype.

Tuberculose — Doença Social

A Tuberculose (TB) em geral é uma doença eminentemente social que, por acaso, tem também implicações médicas. O autor relembra o facto de: ser a TB, a nível mundial, a principal causa de morte por um único agente infeccioso; a incidência e prevalência da TB serem elevadíssimas a nível planetário e não terem tendência para descer, antes pelo contrário; persistirem programas inadequados ao controlo da situação, quer nos países desenvolvidos, quer nos países em desenvolvimento. Enumeram-se as várias condicionantes para esta situação, sendo a pobreza generalizada, a falta de condições mínimas de habitabilidade e a imunodepressão de causa infecciosa (Ex.: VIH) e gerontológica as principais. Em Portugal, país desde há décadas integrado em comunidades de países desenvolvidos (EFTA, CEE, UE), as taxas de incidência de TB continuam elevadas porque apresenta factores sociais de risco comuns aos países desenvolvidos e aos países em desenvolvimento associados a faltas de organização, já que nunca existiu uma política coerente de luta contra a Tuberculose... Para este combate, que o autor considera um imperativo nacional, devem ser rapidamente disponibilizados os meios financeiros, técnicos e humanos necessários.

Long-Term Lamivudine Treatment of Children with Chronic Hepatitis B: Durability of Therapeutic Responses and Safety

Lamivudine has been demonstrated safe and efficacious in the short term in a large cohort of children with chronic hepatitis B (CHB), but optimal duration of treatment has not been elucidated and limited data on the safety of long-term lamivudine administration have been reported. In addition, the durability of favourable therapeutic outcomes after lamivudine therapy in children has not been well characterized. The aim of this study was to examine the safety of lamivudine and the durability of clinical responses in a group of children who received up to 3 years of treatment for CHB. One hundred and fifty-one children from centres in nine countries who had previously received lamivudine in a large prospective trial were enrolled. During the first year, children had been randomized to either lamivudine or placebo treatment. Subsequently, in a separate extension study, those who remained hepatitis B e antigen (HBeAg) positive were given lamivudine for up to 2 years and those who were HBeAg negative were observed for additional 2 years. Results of these studies have been previously reported. In this study, these children were followed for 2 additional years. Data gathered from medical record review included weight, height, signs and symptoms of hepatitis, alanine aminotransferase (ALT) levels, serologic markers, hepatitis B virus (HBV) DNA levels and serious adverse events (SAEs). Other pharmacological treatments for CHB were allowed according to the practices of individual investigators and were documented. Subjects were divided into two groups for analysis, those who had achieved virological response (VR), defined as HBeAg negative and undetectable HBV DNA by the bDNA assay by the end of the extension study at 3 years, and those who had not. In those who had achieved VR by the end of the extension study, long-term durability of HBeAg seroconversion was 82% and >90% in those who had received lamivudine for 52 weeks and at least 2 years respectively. This compares to 75% for those who had achieved seroconversion after placebo. In those who had not achieved VR by the end of the extension study, an additional 11% did so by the end of the study; they had all received lamivudine in the previous trial, and none had received further treatment during the study. Eight children lost hepatitis B surface antigen during the study and all had received lamivudine at some point during the previous trials. Evaluation of safety data revealed no SAEs related to lamivudine. There was no effect of treatment on weight or height z scores. Clinically benign ALT flares (>10 times normal) were seen in 2% of children. Favourable outcomes from lamivudine treatment of CHB in children are maintained for at least several years after completion of treatment. Up to 3 years of lamivudine treatment is safe in children.